Compare ADMA Biologics Inc (ADMA) vs CDW Corp. (CDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs CDW Corp. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while CDW Corp. trades at $137.92 (market cap $17.79B). The key difference: CDW Corp. is far larger — about 8.4× ADMA Biologics Inc's market cap, and CDW Corp. pays a 1.81% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CDW | |
|---|---|---|
Market Cap | $2.13B | $17.79B |
Sector | Health | Technology |
52-Week High | $20.38 | $182.18 |
52-Week Low | $7.60 | $99.30 |
Enterprise Value | $2.20B | $23.00B |
Dividend Yield | — | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CDW trades at $139.23, up 4.39% today, near its consensus price target of $142.17. The stock shows a bullish technical trend with strong moving averages, while fundamentals reflect steady revenue of $22.42B in 2025 and robust profitability with a 44.16% ROE. Recent news highlights AI infrastructure demand fueling growth, and the company increased its share repurchase program by $1 billion in May 2026.
Outlook is positive with analyst consensus strongly bullish (70.59% buy ratings), though risks include margin pressure and competitive threats. The stock offers value with a P/E of 16.34 and growth potential from AI adoption, but investors should monitor execution on earnings targets and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
